Evidence map›Paper›PMID 32536965›Full record

ArticleChinese medicine2020

Mechanism of Dayuanyin in the treatment of coronavirus disease 2019 based on network pharmacology and molecular docking.

Xiaofeng Ruan, Peng Du, Kang Zhao, Jucun Huang, Hongmei Xia, Dan Dai, Shu Huang, Xiang Cui, Liming Liu, Jianjun Zhang

Abstract read
In one paragraph

Article in Chinese medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Compounds of plants with activity against SARS-CoV-2 targets.Expert review of clinical pharmacology · 2021
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2023
    Article
  13. Review
  14. Review
  15. Article
  16. Uncovering the effects and molecular mechanism ofFrontiers in pharmacology · 2023
    Article
  17. Article
  18. Network pharmacology andAnnals of medicine · 2022
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaofeng Ruan *College of Traditional Chinese Medicine, Hubei University of Traditional Chinese Medicine, Wuhan, 430070 China.
Peng Du *Department of Rehabilitation Medicine, Xiangyang Central Hospital, Xiangyang, 441021 Hubei China.
Kang ZhaoDepartment of Liver Medicine, Hubei NO.3 People's Hospital of Jianghan University, Wuhan, 430033 China.
Jucun HuangDepartment of Liver Medicine, Hubei NO.3 People's Hospital of Jianghan University, Wuhan, 430033 China.
Hongmei XiaDepartment of Liver Medicine, Hubei NO.3 People's Hospital of Jianghan University, Wuhan, 430033 China.
Dan DaiDepartment of Liver Medicine, Hubei NO.3 People's Hospital of Jianghan University, Wuhan, 430033 China.
Shu HuangDepartment of Liver Medicine, Hubei NO.3 People's Hospital of Jianghan University, Wuhan, 430033 China.
Xiang CuiDepartment of Liver Medicine, AnKang Hospital of Traditional Chinese Medicine, Ankang, 72500 Shaanxi China.
Liming LiuCollege of Traditional Chinese Medicine, Hubei University of Traditional Chinese Medicine, Wuhan, 430070 China.ORCID 0000-0002-4581-7730
Jianjun ZhangCollege of Traditional Chinese Medicine, Hubei University of Traditional Chinese Medicine, Wuhan, 430070 China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAt present, coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2, is spreading all over the world, with disastrous consequences for people of all countries. The traditional Chinese medicine prescription Dayuanyin (DYY), a classic prescription for the treatment of plague, has shown significant effects in the treatment of COVID-19. However, its specific mechanism of action has not yet been clarified. This study aims to explore the mechanism of action of DYY in the treatment of COVID-19 with the hope of providing a theoretical basis for its clinical application.

methodsFirst, the TCMSP database was searched to screen the active ingredients and corresponding target genes of the DYY prescription and to further identify the core compounds in the active ingredient. Simultaneously, the Genecards database was searched to identify targets related to COVID-19. Then, the STRING database was applied to analyse protein-protein interaction, and Cytoscape software was used to draw a network diagram. The R language and DAVID database were used to analyse GO biological processes and KEGG pathway enrichment. Second, AutoDock Vina and other software were used for molecular docking of core targets and core compounds. Finally, before and after application of DYY, the core target gene IL6 of COVID-19 patients was detected by ELISA to validate the clinical effects.

resultsFirst, 174 compounds, 7053 target genes of DYY and 251 genes related to COVID-19 were selected, among which there were 45 target genes of DYY associated with treatment of COVID-19. This study demonstrated that the use of DYY in the treatment of COVID-19 involved a variety of biological processes, and DYY acted on key targets such as IL6, ILIB, and CCL2 through signaling pathways such as the IL-17 signaling pathway, AGE-RAGE signaling pathway in diabetic complications, and cytokine-cytokine receptor interaction. DYY might play a vital role in treating COVID-19 by suppressing the inflammatory storm and regulating immune function. Second, the molecular docking results showed that there was a certain affinity between the core compounds (kaempferol, quercetin, 7-Methoxy-2-methyl isoflavone, naringenin, formononetin) and core target genes (IL6, IL1B, CCL2). Finally, clinical studies showed that the level of IL6 was elevated in COVID-19 patients, and DYY can reduce its levels.

conclusionsDYY may treat COVID-19 through multiple targets, multiple channels, and multiple pathways and is worthy of clinical application and promotion.

Indexed as

Coronavirus disease 2019DayuanyinMechanism researchMolecular dockingNetwork pharmacology

Identifiers

PMID32536965
PMCPMC7289712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.